The present disclosure relates to a respiratory treatment device, and in particular, to an oscillating positive respiratory pressure device.
Each day, humans may produce upwards of 30 milliliters of sputum, which is a type of bronchial secretion. Normally, an effective cough is sufficient to loosen secretions and clear them from the body's airways. However, for individuals suffering from more significant bronchial obstructions, such as collapsed airways, a single cough may be insufficient to clear the obstructions.
One type of therapy, utilizing oscillating positive expiratory pressure (“OPEP”), is often used to address this issue. OPEP therapy represents an effective bronchial hygiene technique for the removal of bronchial secretions in the human body and is an important aspect in the treatment and continuing care of patients with bronchial obstructions, such as those suffering from chronic obstructive lung disease. It is believed that OPEP therapy, or the oscillation of exhalation pressure at the mouth during exhalation, effectively transmits an oscillating back pressure to the lungs, thereby splitting open obstructed airways and loosening the secretions contributing to bronchial obstructions.
OPEP therapy is an attractive form of treatment because it can be easily taught to most hospitalized patients, and such patients can assume responsibility for the administration of OPEP therapy throughout their hospitalization and also once they have returned home. To that end, a number of portable OPEP devices have been developed.
In one aspect, a respiratory treatment device includes a housing enclosing a chamber, a chamber inlet configured to receive a flow of air into the chamber, a first chamber outlet configured to permit the flow of air to exit the chamber, and a second chamber outlet configured to permit the flow of air to exit the chamber. A vane mounted within the chamber is configured to rotate between a first position where the flow of air is directed to exit the chamber through the first chamber outlet, and a second position where the flow of air is directed to exit the chamber through the second chamber outlet. A blocking member disposed on the vane is moveable relative to the chamber inlet between a closed position where the flow of air through the chamber inlet is restricted, and an open position where the flow of air through the chamber inlet is less restricted.
In another aspect, the vane may be configured to rotate in response to the flow of air into the chamber. The vane may be configured to repeatedly reciprocate between the first position and the second position in response to the flow of air into the chamber. The vane may also be prohibited from completing a complete revolution.
In another aspect, a size of the blocking member may be greater than a size of the chamber inlet. Alternatively, a size of the blocking member may be less than a size of the chamber inlet.
In another aspect, an axis of rotation of the vane may be offset from a center of the vane.
In another aspect, the respiratory treatment also includes a mouthpiece, wherein a cross sectional area of the mouthpiece is larger than a cross sectional area of the chamber inlet. In addition, an inhalation port may be in communication with the mouthpiece, the inhalation port having a one-way valve configured to open upon inhalation and close upon exhalation.
In yet another aspect, a respiratory treatment device includes a housing enclosing a chamber, an inlet configured to receive a flow of air into the chamber, and an outlet configured to permit the flow of air to exit chamber. A blocking member mounted in the chamber is moveable relative to the chamber outlet between a closed position where the flow of air through the exit is restricted, and an open position where the flow of air through the chamber outlet is less restricted. At least one vane rotatably mounted in the chamber is configured to move the blocking member between the closed position and the open position in response to the flow of air into the chamber.
In another aspect, the blocking member may be connected to the at least one vane by a shaft and at least one linkage. The shaft and the at least one linkage may cooperate to move the blocking member in linear reciprocating motion.
In another aspect, the blocking member may be configured to move between the open position and the closed position in response to contact from an arm connected to the at least one vane.
In another aspect, the blocking member may be biased toward the open position.
In another aspect, the at least one vane comprises a turbine having a plurality of vanes.
In another aspect, the chamber comprises a first portion enclosing the at least one vane and a second portion enclosing the blocking member. The first portion may be in communication with the second portion.
In another aspect, the respiratory treatment also includes a mouthpiece, wherein a cross sectional area of the mouthpiece is larger than a cross sectional area of the chamber inlet. In addition, an inhalation port may be in communication with the mouthpiece, the inhalation port having a one-way valve configured to open upon inhalation and close upon exhalation.
In yet another aspect, a method of performing respiratory treatment includes receiving a flow of air into a device having an inlet configured to receive a flow of air into the device, a first outlet configured to permit the flow air to exit the device, and a second outlet configured to permit the flow of air to exit the device. The method further includes rotating a vane mounted within the device repeatedly between a first position where the flow of air is directed to exit the chamber through the first chamber outlet, and a second position where the flow of air is directed to exit the chamber through the second chamber outlet. The method also includes moving a blocking member disposed on the vane relative to the chamber inlet between a closed position where the flow of air through the chamber inlet is restricted, and an open position where the flow of air through the chamber inlet is less restricted.
Referring to
The housing 102 and OPEP device 100 components may be constructed of any durable material, such as a low friction plastic or polymer, and may include a front section 103 and a rear section 105 that are removably attachable such that the chamber 104 may be periodically accessed for cleaning and/or replacement of the vane 114. In addition, although the mouthpiece 112 is shown as being fixedly attached to the housing 102, it is envisioned that the mouthpiece 112 may be removeable and replaceable with a mouthpiece of a different shape or size. Preferably, the size or cross-sectional area of the mouthpiece 112 is greater than the size or cross-sectional area of the chamber inlet 106. It is envisioned that other user interfaces, such as breathing tubes or gas masks (not shown), may alternatively be associated with the housing 102.
As shown in
The operation of the OPEP device 100 will now be described with reference to the illustrations shown in
As shown in
As a user continues to exhale, the vane 114 rotates from the position shown in
As a user continues to exhale, the vane 114 rotates from the position shown in
As the vane 114 continues to rotate in a clockwise direction, the vane 114 rotates from the position shown in
As the vane 114 continues to rotate in a clockwise direction, the vane 114 rotates from the position shown in
During a period of exhalation, the vane 114 rotates repeatedly between the first position and the second position in clockwise and counter-counterclockwise directions. As this movement is repeated, the blocking member 116 moves repeatedly between a closed position, where the flow of air through the chamber inlet 106 is restricted by the blocking member 116, and an open position, where the flow of air through the chamber inlet 106 is less restricted. Consequently, the pressure in the mouthpiece 112, or user interface, oscillates between a higher pressure and a lower pressure, which pressures are in turn transmitted to the user's airways, thereby administering OPEP therapy.
Turning to
As shown in
Referring to
The housing 202 and OPEP device 200 components may be constructed of any durable material, such as a low friction plastic or polymer, and may include a front cover 203 and a rear cover 205 that are removably attachable such that the chamber 204 may be periodically accessed for cleaning and/or replacement of the turbine 214 and/or linkages 220, 222. In addition, although the mouthpiece 212 is shown as being fixedly attached to the housing 202, it is envisioned that the mouthpiece 212 may be removeable and replaceable with a mouthpiece of a different shape or size. Preferably, the size or cross-sectional area of the mouthpiece 212 is greater than the size or cross-sectional area of the chamber inlet 206. It is envisioned that other user interfaces, such as breathing tubes or gas masks (not shown), may alternatively be associated with the housing 202.
As shown in
As shown in
The operation of the OPEP device 200 will now be described with reference to the illustrations shown in
In general, administration of OPEP therapy using the OPEP device 200 begins with the blocking member 216 in an open position, as shown in
Turning to
The housing 302 and OPEP device 300 components may be constructed of any durable material, such as a low friction plastic or polymer, and may include an upper section 303, an inner section 301, and a lower section 305 that are removably attachable such that the chamber 304 may be periodically accessed for cleaning and/or replacement of the turbine 314. In addition, although the mouthpiece 312 is shown as being fixedly attached to the housing 302, it is envisioned that the mouthpiece 312 may be removeable and replaceable with a mouthpiece of a different shape or size. Preferably, the size or cross-sectional area of the mouthpiece 312 is greater than the size or cross-sectional area of the chamber inlet 306. It is envisioned that other user interfaces, such as breathing tubes or gas masks (not shown), may alternatively be associated with the housing 302.
Turning to
The blocking member 316 is mounted to the inner section 301 of the housing 302 about a pair of hinges 328, 330, such that the blocking member 316 may rotate relative to the chamber outlet 308 between a closed position, as shown in
The operation of the OPEP device 300 will now be described with reference to the illustration shown in
In general, administration of OPEP therapy using the OPEP device 300 begins with the blocking member 316 in an open position, as shown in
As a user continues to exhale, and the turbine 314 continues to rotate, the shaft 318 rotates, causing the pair of arms 320, 322 to also rotate. As the pair of arms 320, 322 rotate, they periodically engage the contact surfaces 332, 334 on the blocking member 316, as shown in
Finally, as best seen in
Although the description of the embodiments described above refer to the administration of OPEP therapy on exhalation, it should be appreciated that such embodiments are also configurable for the administration of oscillating pressure therapy upon exhalation only, inhalation only, or both exhalation and inhalation. Accordingly, the terms “oscillating positive respiratory pressure” and “oscillating positive expiratory pressure,” or “OPEP,” may be used interchangeably. Similarly, the term “respiratory” may refer to inhalation, exhalation, or both inhalation and exhalation. Use of any such term should not be construed as a limitation to only inhalation or only exhalation.
The foregoing description of the inventions has been presented for purposes of illustration and description, and is not intended to be exhaustive or to limit the inventions to the precise forms disclosed. It will be apparent to those skilled in the art that the present inventions are susceptible of many variations and modifications coming within the scope of the following claims.
This application is a continuation of U.S. application Ser. No. 15/819,150, filed on Nov. 21, 2017, pending, which is a continuation of U.S. application Ser. No. 14/462,009, filed on Aug. 18, 2014, now U.S. Pat. No. 9,849,257, which claims the benefit of U.S. Provisional Application No. 61/868,667, filed on Aug. 22, 2013, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
393869 | Warren | Dec 1888 | A |
938808 | Yount | Nov 1909 | A |
2670739 | NcNeill | Mar 1954 | A |
2918917 | Emerson | Dec 1959 | A |
3710780 | Milch | Jan 1973 | A |
3732864 | Thompson et al. | May 1973 | A |
3834383 | Weigl et al. | Sep 1974 | A |
3908987 | Boehringer | Sep 1975 | A |
4054134 | Kritzer | Oct 1977 | A |
4062358 | Kritzer | Dec 1977 | A |
4182366 | Boehringer | Jan 1980 | A |
4198969 | Virag | Apr 1980 | A |
4221381 | Ericson | Sep 1980 | A |
4226233 | Kritzer | Oct 1980 | A |
4231375 | Boehringer et al. | Nov 1980 | A |
4267832 | Hakkinen | May 1981 | A |
4275722 | Sorensen | Jun 1981 | A |
4298023 | McGinnis | Nov 1981 | A |
4327740 | Shuman | May 1982 | A |
4403616 | King | Sep 1983 | A |
4436090 | Darling | Mar 1984 | A |
4470412 | Nowacki et al. | Sep 1984 | A |
4601465 | Roy | Jul 1986 | A |
4611591 | Inui et al. | Sep 1986 | A |
4635631 | Izumi | Jan 1987 | A |
4651731 | Vicenzi et al. | Mar 1987 | A |
4739987 | Nicholson | Apr 1988 | A |
4770413 | Green | Sep 1988 | A |
4951661 | Sladek | Aug 1990 | A |
4973047 | Norell | Nov 1990 | A |
4981295 | Belman et al. | Jan 1991 | A |
5018517 | Liardet | May 1991 | A |
5042467 | Foley | Aug 1991 | A |
5065746 | Steen | Nov 1991 | A |
5193529 | Labaere | Mar 1993 | A |
5253651 | Stockwell et al. | Oct 1993 | A |
5277195 | Williams | Jan 1994 | A |
5345930 | Cardinal et al. | Sep 1994 | A |
5372128 | Haber et al. | Dec 1994 | A |
5381789 | Marquardt | Jan 1995 | A |
5413112 | Jansen et al. | May 1995 | A |
5451190 | Liardet | Sep 1995 | A |
5479920 | Piper et al. | Jan 1996 | A |
5540220 | Gropper et al. | Jul 1996 | A |
5569122 | Cegla | Oct 1996 | A |
5570682 | Johnson | Nov 1996 | A |
5598839 | Niles et al. | Feb 1997 | A |
5613489 | Miller | Mar 1997 | A |
5613497 | DeBush | Mar 1997 | A |
5645049 | Foley et al. | Jul 1997 | A |
5647345 | Saul | Jul 1997 | A |
5655520 | Howe | Aug 1997 | A |
5658221 | Hougen | Aug 1997 | A |
5687912 | Denyer | Nov 1997 | A |
5727546 | Clarke et al. | Mar 1998 | A |
5791339 | Winter | Aug 1998 | A |
5816246 | Mirza | Oct 1998 | A |
5823183 | Casper et al. | Oct 1998 | A |
5829429 | Hughes | Nov 1998 | A |
5848588 | Foley et al. | Dec 1998 | A |
5862802 | Bird | Jan 1999 | A |
5890998 | Hougen | Apr 1999 | A |
5893361 | Hughes | Apr 1999 | A |
5899832 | Hougen | May 1999 | A |
5910071 | Hougen | Jun 1999 | A |
5925831 | Storsved | Jul 1999 | A |
5988163 | Casper et al. | Nov 1999 | A |
5988166 | Hayek | Nov 1999 | A |
6026807 | Puderbaugh et al. | Feb 2000 | A |
6029661 | Whaley et al. | Feb 2000 | A |
6044841 | Verdun et al. | Apr 2000 | A |
6058932 | Hughes | May 2000 | A |
6066101 | Johnson | May 2000 | A |
6067984 | Piper | May 2000 | A |
6083141 | Hougen | Jul 2000 | A |
6089105 | Ricciardelli | Jul 2000 | A |
6102038 | DeVries | Aug 2000 | A |
6167881 | Hughes | Jan 2001 | B1 |
6176235 | Benarrouch et al. | Jan 2001 | B1 |
6182657 | Brydon et al. | Feb 2001 | B1 |
D440651 | Foran | Apr 2001 | S |
6209538 | Casper et al. | Apr 2001 | B1 |
6240917 | Andrade | Jun 2001 | B1 |
6253766 | Niles | Jul 2001 | B1 |
6269839 | Wickham et al. | Aug 2001 | B1 |
6293279 | Schmidt et al. | Sep 2001 | B1 |
6340025 | Van Brunt | Jan 2002 | B1 |
6345617 | Engelbreth et al. | Feb 2002 | B1 |
6412481 | Bienvenu et al. | Jul 2002 | B1 |
6446629 | Takaki et al. | Sep 2002 | B1 |
6447459 | Larom | Sep 2002 | B1 |
6500095 | Hougen | Dec 2002 | B1 |
6550477 | Casper et al. | Apr 2003 | B1 |
6557549 | Schmidt et al. | May 2003 | B2 |
6561186 | Casper et al. | May 2003 | B2 |
6581595 | Murdock et al. | Jun 2003 | B1 |
6581596 | Truitt | Jun 2003 | B1 |
6581598 | Foran et al. | Jun 2003 | B1 |
6581600 | Bird | Jun 2003 | B2 |
6595203 | Bird | Jul 2003 | B1 |
6606989 | Brand | Aug 2003 | B1 |
6607008 | Yoshimoto et al. | Aug 2003 | B1 |
6615831 | Truitt | Sep 2003 | B1 |
6631721 | Salter et al. | Oct 2003 | B1 |
6659100 | O'Rourke | Dec 2003 | B2 |
6681768 | Haaije de Boer et al. | Jan 2004 | B2 |
6702769 | Fowler/Hawkins | Mar 2004 | B1 |
6708690 | Hete et al. | Mar 2004 | B1 |
6708691 | Hayek | Mar 2004 | B1 |
6726598 | Jarvis | Apr 2004 | B1 |
D490519 | Pelerossi et al. | May 2004 | S |
6776159 | Pelerossi et al. | Aug 2004 | B2 |
6848443 | Schmidt et al. | Feb 2005 | B2 |
6851425 | Jaffre | Feb 2005 | B2 |
6889564 | Marcotte et al. | May 2005 | B1 |
6904906 | Salter | Jun 2005 | B2 |
6923181 | Tuck | Aug 2005 | B2 |
6929007 | Emerson | Aug 2005 | B2 |
6984214 | Fowler/Hawkins | Jan 2006 | B2 |
7059324 | Pelerossi et al. | Jun 2006 | B2 |
7096866 | Be'eri et al. | Aug 2006 | B2 |
7134434 | Truitt et al. | Nov 2006 | B2 |
7165547 | Truitt et al. | Jan 2007 | B2 |
7188621 | DeVries | Mar 2007 | B2 |
7191776 | Niles | Mar 2007 | B2 |
7191780 | Faram | Mar 2007 | B2 |
7214170 | Summers et al. | May 2007 | B2 |
7383740 | Krasilchikov et al. | Jun 2008 | B2 |
7617821 | Hughes | Nov 2009 | B2 |
7699054 | Pelerossi et al. | Apr 2010 | B2 |
7717847 | Smith | May 2010 | B2 |
7771472 | Hendricksen | Aug 2010 | B2 |
7779841 | Dunsmore et al. | Aug 2010 | B2 |
7798148 | Doshi | Sep 2010 | B2 |
7856979 | Doshi | Dec 2010 | B2 |
7905228 | Blacker et al. | Mar 2011 | B2 |
7909033 | Faram | Mar 2011 | B2 |
8006922 | Katzer | Aug 2011 | B2 |
8025051 | Dagsland | Sep 2011 | B2 |
8025054 | Dunsmore et al. | Sep 2011 | B2 |
8043236 | Goldshtein et al. | Oct 2011 | B2 |
8051854 | Faram | Nov 2011 | B2 |
RE43174 | Schmidt et al. | Feb 2012 | E |
8118024 | DeVries et al. | Feb 2012 | B2 |
8118713 | Foley et al. | Feb 2012 | B2 |
8225785 | Richards et al. | Jul 2012 | B2 |
8327849 | Grychowski et al. | Dec 2012 | B2 |
8360061 | Brown et al. | Jan 2013 | B2 |
8460223 | Huster et al. | Jun 2013 | B2 |
8469029 | Brown et al. | Jun 2013 | B2 |
8485179 | Meyer | Jul 2013 | B1 |
8528547 | Dunsmore et al. | Sep 2013 | B2 |
8539951 | Meyer et al. | Sep 2013 | B1 |
8985111 | Grychowski et al. | Mar 2015 | B2 |
8993774 | Kanbara et al. | Mar 2015 | B2 |
D731050 | Meyer | Jun 2015 | S |
9149589 | Meyer et al. | Oct 2015 | B2 |
9220855 | Meyer | Dec 2015 | B2 |
9358417 | Meyer | Jun 2016 | B2 |
9517315 | Meyer | Dec 2016 | B2 |
D776804 | Meyer | Jan 2017 | S |
D778429 | Engelbreth et al. | Feb 2017 | S |
D780906 | Engelbreth et al. | Mar 2017 | S |
9636473 | Meyer | May 2017 | B2 |
9737677 | Grychowski et al. | Aug 2017 | B2 |
9808588 | Meyer et al. | Nov 2017 | B1 |
9849257 | Meyer | Dec 2017 | B2 |
9913955 | Grychowski et al. | Mar 2018 | B2 |
9950128 | Meyer et al. | Apr 2018 | B2 |
9981106 | Meyer et al. | May 2018 | B2 |
10039691 | Von Hollen | Aug 2018 | B2 |
10076616 | Meyer et al. | Sep 2018 | B2 |
10272224 | Costella et al. | Apr 2019 | B2 |
10363383 | Alizoti et al. | Jul 2019 | B2 |
10413698 | Meyer et al. | Sep 2019 | B2 |
10449324 | Meyer et al. | Oct 2019 | B2 |
20030015195 | Haaije de Boer et al. | Jan 2003 | A1 |
20060032607 | Wisniewski | Feb 2006 | A1 |
20070089740 | Baumert et al. | Apr 2007 | A1 |
20070259759 | Sumners et al. | Nov 2007 | A1 |
20080078383 | Richards et al. | Apr 2008 | A1 |
20080245368 | Dunsmore et al. | Oct 2008 | A1 |
20080257348 | Piper | Oct 2008 | A1 |
20090241949 | Smutney et al. | Oct 2009 | A1 |
20100139655 | Genosar | Jun 2010 | A1 |
20100307487 | Dunsmore et al. | Dec 2010 | A1 |
20120097164 | Rozario et al. | Apr 2012 | A1 |
20150374939 | Meyer et al. | Dec 2015 | A1 |
20170049979 | Meyer et al. | Feb 2017 | A1 |
20170128683 | Meyer et al. | May 2017 | A1 |
20170312461 | Grychowski et al. | Nov 2017 | A1 |
20180154093 | Meyer et al. | Jun 2018 | A1 |
20180214662 | Meyer et al. | Aug 2018 | A1 |
20180256839 | Meyer et al. | Sep 2018 | A1 |
20190240533 | Alizoti | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
201329062 | Oct 2009 | CN |
0 372 148 | Jun 1990 | EP |
0 678 306 | Oct 1995 | EP |
1 464 357 | Oct 2004 | EP |
1 435 251 | Jun 2006 | EP |
1 103 287 | Jun 2007 | EP |
1 897 576 | Mar 2008 | EP |
1 908 489 | Apr 2008 | EP |
2444114 | Apr 2012 | EP |
2455137 | May 2012 | EP |
2 425 488 | Nov 2006 | GB |
2010-523220 | Jul 2010 | JP |
WO 198903707 | May 1989 | WO |
WO 199640376 | Dec 1996 | WO |
WO 199916490 | Apr 1999 | WO |
WO 200027455 | May 2000 | WO |
WO 2007061648 | May 2007 | WO |
WO 2007119104 | Oct 2007 | WO |
WO 2008063966 | May 2008 | WO |
WO 2008122045 | Oct 2008 | WO |
WO 2009131965 | Oct 2009 | WO |
WO 2011058470 | May 2011 | WO |
WO 2012038864 | Mar 2012 | WO |
WO 2016012740 | Jan 2016 | WO |
Entry |
---|
U.S. Appl. No. 14/674,494, filed Mar. 31, 2015, Meyer et al. |
Web page entitled Bronchial Hygiene, acapella Vibratory PEP Therapy System accessed from http://www.smiths/medical.com/catalog/bronchial/hygiene/acapella/acapella.html on Jul. 7, 2009. |
Web page entitled Thayer Quake accessed from http://www.thayermedical.com/quake.htm on Jul. 7, 2009. |
Human growth hormone, cortisol, and acid/base balance changes after hyperventilation and breath/holding; PubMed—indexed for Medline; Int J Sports Med., Dec. 1986; 7(6):311/5, Djarova T. |
Bosco C, Cardinale M. & Tsarpela O (1999). Influence of vibration on mechanical power and electromyogram activity in human arm flexor muscles. Eur J Appl Physiol 79, 306/311. |
David Sumners; Power Breathing and Strength; http://EzineArticles.com/972576 Published: Feb. 7, 2008. |
Good Vibrations blog; http://vibrotraining.blogspot.com. Earliest posting Jan. 17, 2008. |
Breathtaking News; More Youbreathe; Aug. 10, 2007. |
PCT International Search Report for PCT/IB2012/001089, Oct. 5, 2012. |
PCT International Written Opinion for PCT/IB2012/001089, Oct. 5, 2012. |
Preliminary Report on Patentability, PCT/IB2012/001089, Dec. 10, 2013. |
PCT/IB2012001089 European Search Report dated Nov. 6, 2014. |
IPR2018/01025 Petition; D R Burton Healthcare LLC v. Trudell Medical International; Title: Oscillating Postive Respiratory Pressure Device; (94 pp). |
D R Burton Healthcare LLC v. Trudell Medical International; “Patent Owner's Preliminary Response to Petition for Inter Partes Review”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588; Sep. 7, 2018; 107 pages. |
D R Burton Healthcare LLC v. Trudell Medical International; “Declaration of Dr. William W. Durgin, Ph.D., In Support of Patent Owner's Preliminary Response to Petition for Inter Partes Review”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588; Trudell Medical Exhibit 2001/00001-2001/00217; 217 pages. |
D R Burton Helathcare LLC v. Trudell Medical International; “Petitioner's Reply to Patent Owner Preliminary Response”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588 B1; Oct. 9, 2018; 16 pages. |
D R Burton Healthcare LLC v. Trudell Medical International; “Decision Denying Institution of Inter Partes Review”; Case No. IPR2018/01025, U.S. Pat. No. 9,808,588 B1; Nov. 29, 2018; 32 pages. |
Number | Date | Country | |
---|---|---|---|
20210060272 A1 | Mar 2021 | US |
Number | Date | Country | |
---|---|---|---|
61868667 | Aug 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15819150 | Nov 2017 | US |
Child | 17028263 | US | |
Parent | 14462009 | Aug 2014 | US |
Child | 15819150 | US |